Liminal Biosciences Receivables

Liminal Biosciences (LMNL) currently reports a receivables of $790K as of June 2023. That compares with $1.5M in the prior-year period — down 46.8% year over year. Use the charts on this page to explore Liminal Biosciences's receivables history and peer comparisons.

Liminal Biosciences's receivables decreased from $1.5M to $790K — a 46.8% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Liminal Biosciences reported $790K in receivables as of June 2023. That compares with $1.5M in the prior-year period — down 46.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $790K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Liminal Biosciences, and consider following LMNL for alerts when major investors trade the stock.

Liminal Biosciences is classified in the Healthcare sector. On receivables, it currently shows $790K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LMNL with unrelated industries.